CHECKLIST: IS YOUR MHSPC PATIENT ELIGIBLE FOR NUBEQA® (DAROLUTAMIDE) + ADT IN COMBINATION WITH DOCETAXEL?

NUBEQA is the only ARi licensed to significantly extend OS* in mHSPC in combination with ADT + docetaxel vs. placebo + ADT + docetaxel*[1,2,3,4]

Patients should meet the following criteria:[1,5]

Adult men with diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

Currently received no more than 12 weeks adrogen deprivation therapy (ADT) for metastatic prostate cancer OR not yet received ADT for metastatic prostate cancer	☑
Fit enough for docetaxel chemotherapy, but not yet commenced upfront docetaxel chemotherapy for mHSPC	☑
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1	☑

If your patient meets these criteria (not an exhaustive list), they may be eligible for NUBEQA + ADT in combination with docetaxel. The first of 6 cycles of docetaxel should be administered within 6 weeks after the start of NUBEQA treatment.
The recommendation in the product information of docetaxel should be followed. Treatment with NUBEQA should be continued until disease progression or unacceptable toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued.[2] Please refer to the NUBEQA Summary of Product Characteristics and the Blueteq funding criteria[5] to prescribe NUBEQA + ADT in combination with docetaxel for your patients.
If you wish to know more about NUBEQA please visit https://pro.bayer.co.uk/oncology-homepage.

* NUBEQA + ADT + doxetaxel: 32.5% reduced risk of death vs. placebo + ADT + docetaxel (95% CI 0.57-0.80 P<0.001).[1,2] A phase 3 randomised double-blind trial (ARASENS) involving 1,306 patients. The primary endpoint was overall survival.

NUBEQA® (darolutamide) 300 mg tablets

Prescribing information and adverse event reporting information for NUBEQA® (darolutamide) is available via the QR code on the right.

Either click here or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

1. Smith MR et al. *N Engl J Med.* 2022;383(12): 1132-1142
2. Nubeqa (darolutamide) Summary of Product Characeteristics. Available at: www.medicines.org.uk/emc/product/11324/smpc (Accessed February 2025)
3. Xtandi (enzalutamide) Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/10318/smpc (Accessed February 2025)
4. Erleada (apautamide) Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/9832/smpc (Accessed February 2025)
5. Cancer Drugs Fund list. Available at: www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/ (Accessed February 2025)

ADT, androgen deprivation therapy; ARi, androgen receptor inhibitor; ECOG, Eastern Cooperative Oncology Group; mHSPC, metastatic hormone-sensitive prostate cancer

Bayer plc
400 South Oak Way
Reading, RG2 6AD
Great Britain

PP-NUB-GB-2076 | February 2025

NUBEQA® (darolutamide) 300 mg tablets